All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @alexismpotter on TikTok · 17s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @alexismpotter's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00This shit I did my big one next year. I'm going pick up you think you hate me now
  2. 0:05I'm about the hurt your feelings. I'm putting up points on the board
  3. 0:09In the shake of the deal. I'm bored you think I'm sexy now this ain't need my final form
  4. 0:14Get it spaghetti my chain is heavy your penis

Six months on GLP-1: separating the real results from the hype

Alexis 🫶🏼🌻

TikTok creator

24.2K viewsWatch on TikTok

Quick answer

The video's caption describes six months of GLP-1 therapy with subjective reports of weight loss and improved wellbeing, consistent with outcomes documented in the STEP and SURMOUNT clinical trial series. However, the spoken audio content contains no medically relevant statements and appears to be unrelated audio overlaid on or misattributed to this video. Any clinical claims in this video are implied by the written caption and hashtag context, not by the creator's spoken words.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Six months on GLP-1: separating the real results from the hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Six months on GLP-1: separating the real results from the hype is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Six months on GLP-1: separating the real results from the hype" from Alexis 🫶🏼🌻. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video's caption describes six months of GLP-1 therapy with subjective reports of weight loss and improved wellbeing, consistent with outcomes documented in the STEP and SURMOUNT clinical trial series.

The reason this review is not generic is the source wording and the canonical claim label "glp1 6 months on glp 1 and wow honestly i didn t think i d make i." In this clip, the useful excerpt is: "This shit I did my big one next year." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

STEP 1 trial (Wilding et al.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video's caption describes six months of GLP-1 therapy with subjective reports of weight loss and improved wellbeing, consistent with outcomes documented in the STEP and SURMOUNT clinical trial series.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video's caption describes six months of GLP-1 therapy with subjective reports of weight loss and improved wellbeing, consistent with outcomes documented in the STEP and SURMOUNT clinical trial series. However, the spoken audio content contains no medically relevant statements and appears to be unrelated audio overlaid on or misattributed to this video. Any clinical claims in this video are implied by the written caption and hashtag context, not by the creator's spoken words.
  • The spoken audio in this video contains no health claims. The fact-check context is drawn entirely from the written caption and hashtag framing.
  • STEP 1 trial (Wilding et al., 2021, NEJM): semaglutide 2.4mg produced 14.9% mean body weight reduction over 68 weeks versus 2.4% on placebo.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The spoken audio in this video contains no health claims. The fact-check context is drawn entirely from the written caption and hashtag framing.
  • STEP 1 trial (Wilding et al., 2021, NEJM): semaglutide 2.4mg produced 14.9% mean body weight reduction over 68 weeks versus 2.4% on placebo.
  • SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM): tirzepatide at the highest dose produced up to 22.5% mean weight reduction, the largest seen in a GLP-1 class trial at that time.
  • Weight regain after stopping is well documented. Rubino et al. (2021) found roughly two-thirds of lost weight returned within 12 months of discontinuing semaglutide.
  • Compounded semaglutide and tirzepatide are not FDA-approved and are not equivalent to brand-name drugs in terms of verified purity or potency standards.
  • Common side effects include nausea, vomiting, and GI discomfort, particularly during dose escalation. Black box warning applies for personal or family history of medullary thyroid carcinoma or MEN2.
  • GLP-1 medications are likely long-term treatments for most people, not short-term interventions. Anyone framing a six-month point as a finish line may be setting inaccurate expectations.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @alexismpotter actually say?

Here is the honest answer: nothing medically relevant. The transcript attributed to this video is not a coherent health claim. The words, "I'm putting up points on the board in the shake of the deal" and "your penis" are not GLP-1 commentary. They appear to be lyrics, a joke, or a badly garbled audio capture, not a first-person account of semaglutide use.

The caption tells a different story. The written framing describes six months on a GLP-1 medication, emotional transformation, and a history of failed weight loss attempts. That narrative is common, relatable, and worth examining on its own terms. But the spoken words in this video do not match that framing at all. Any fact-check of the audio itself would be fact-checking nonsense syllables, so we are working from the caption context and the broader claims implied by the video's framing and hashtags.

Does the science back up the caption's implied claims?

The core implication, that GLP-1 receptor agonists can produce meaningful, sustained weight loss after other interventions have failed, is well supported. This is not influencer wishful thinking. It is one of the more robustly replicated findings in obesity pharmacology right now.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants on semaglutide 2.4mg lost an average of 14.9% of body weight over 68 weeks versus 2.4% on placebo. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced up to 22.5% mean weight reduction at the highest dose. These are not trivial numbers. For people who have cycled through diets, exercise programs, and behavioral interventions without lasting results, GLP-1 and dual GIP/GLP-1 agonists represent a genuinely different mechanism, appetite regulation at the hypothalamic level, not just caloric restriction willpower.

The emotional framing, "reclaiming my life" and "learning to love myself," is harder to quantify but not without basis. Quality-of-life measures in STEP trials showed improvements in physical functioning and self-reported wellbeing alongside weight reduction.

What did they get wrong, or right?

The caption gets the emotional arc right. People who have struggled with weight for years and experienced repeated failure are not weak or undisciplined. The biology of obesity involves leptin resistance, altered satiety signaling, and metabolic adaptation that makes keeping weight off after caloric restriction genuinely difficult. GLP-1 medications work on some of those mechanisms directly.

What the video gets wrong by omission is significant, though. There is no mention of the fact that weight typically returns when people stop the medication. Rubino et al. (2021, Diabetes, Obesity and Metabolism) found that one year after discontinuing semaglutide, participants regained about two-thirds of their lost weight. That is not a reason to avoid GLP-1 therapy, but it is information anyone six months in deserves to have.

The hashtag framing, particularly "healthtransformation" and "takingmylifeback," implies a permanent change. The current evidence suggests these medications are likely long-term or indefinite treatments for most people, not a six-month reset. That distinction matters for anyone watching and making decisions.

What should you actually know?

GLP-1 receptor agonists are not a shortcut, and they are not a cure. They are an effective pharmacological tool with a real evidence base and real side effects. Nausea, vomiting, and gastrointestinal discomfort are common, especially during dose escalation. Rare but serious risks include pancreatitis and, in rodent studies, thyroid C-cell tumors, which is why these medications carry a black box warning for people with a personal or family history of medullary thyroid carcinoma or MEN2.

Compounded versions of semaglutide and tirzepatide have been widely available during shortage periods, but compounded drugs are not FDA-approved and are not equivalent to brand-name formulations in terms of verified potency, purity, or sterility standards. Anyone considering a compounded peptide should understand that distinction clearly before starting.

If you are six months in and feeling good, that is genuinely worth acknowledging. But talk to your prescriber about long-term plans, not TikTok comment sections.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Alexis 🫶🏼🌻 · TikTok creator

24.2K views on this video

6 months on GLP-1… and wow. Honestly, I didn’t think I’d make it this far. When I started, I wasn’t sure what to expect—I’ve tried everything before, and nothing ever worked. But this journey has been more than just weight loss. It’s been about reclaiming my life, learning to love myself in ways I didn’t think were possible, and finally feeling in control instead of defeated. 55.6lbs down, yes—but it’s not just about the number on the scale. It’s about the energy I have, the confidence I feel

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the spoken audio in this video contains no health claims.?

The spoken audio in this video contains no health claims. The fact-check context is drawn entirely from the written caption and hashtag framing.

What does the video say about step 1 trial (wilding et al., 2021, nejm): semaglutide 2.4mg?

STEP 1 trial (Wilding et al., 2021, NEJM): semaglutide 2.4mg produced 14.9% mean body weight reduction over 68 weeks versus 2.4% on placebo.

What does the video say about surmount-1 trial (jastreboff et al., 2022, nejm): tirzepatide at the?

SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM): tirzepatide at the highest dose produced up to 22.5% mean weight reduction, the largest seen in a GLP-1 class trial at that time.

What does the video say about weight regain after stopping?

Weight regain after stopping is well documented. Rubino et al. (2021) found roughly two-thirds of lost weight returned within 12 months of discontinuing semaglutide.

What does the video say about compounded semaglutide?

Compounded semaglutide and tirzepatide are not FDA-approved and are not equivalent to brand-name drugs in terms of verified purity or potency standards.

What does the video say about common side effects include nausea, vomiting,?

Common side effects include nausea, vomiting, and GI discomfort, particularly during dose escalation. Black box warning applies for personal or family history of medullary thyroid carcinoma or MEN2.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Alexis 🫶🏼🌻, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.